Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

33
Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

2018-07-13 seekingalpha
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
SNWW AST ACHV URGN CDXC OVID AUPH SNWV DRNA AKCA TORC AUP AST.WS OSIR AGN MRK IONS NVS ABBV RMD BMY ABBV

4
Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health

2018-07-11 globenewswire
IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus University Hospital, were published yesterday in The American Journal of Clinical Nutrition.
CDXC

4
TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the 2018 Healthy Aging Summit

2018-07-09 globenewswire
IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its flagship consumer product to help improve the aging process, TRU NIAGEN®, at the American Association of Naturopathic Physicians Annual Convention as well as the 2018 Healthy Aging Summit.
CDXC

8
ChromaDex added to membership of US small-cap Russell 2000® Index

2018-06-25 globenewswire
IRVINE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 25, as part of the 2018 Russell indexes reconstitution.
LSE CDXC

37
New Strong Sell Stocks for June 11th

2018-06-11 zacks
Accuray Incorporated (ARAY - Free Report) is a designer and seller of radiosurgery and radiation therapy systems. The Zacks Consensus Estimate for its current year earnings has been revised 52.6% downward over the last 60 days.
BRS APPS HSC AMRB CHA KELYA CDXC KELYB ARAY

6
ChromaDex Appoints Lisa Bratkovich as Chief Marketing Officer

2018-06-04 globenewswire
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Lisa Bratkovich as Chief Marketing Officer, effective today.
CDXC

6
TRU NIAGEN® to be featured at the American Society for Nutrition's Annual Meeting

2018-05-29 globenewswire
IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its novel form of vitamin B3, TRU NIAGEN® (Booth #405), at the American Society for Nutrition's Annual Meeting, a gathering of 2500 scientists, healthcare practitioners, researchers and policy makers, June 9-12 in Boston, MA.
CDXC

9
What Falling Estimates & Price Mean for ChromaDex (CDXC)

2018-05-23 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
CDXC URBN ILMN

6
ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board

2018-05-14 globenewswire
IRVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of Cambridge, England, to the Scientific Advisory Board (SAB).
CDXC

7
ChromaDex Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-11 seekingalpha
The following slide deck was published by ChromaDex Inc. in conjunction with their 2018 Q1 earnings call.
CDXC

6
ChromaDex's (CDXC) CEO Frank Jaksch on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's First Quarter 2018 Earnings Conference Call. My name is Daniel, and I will be the conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded. This afternoon, ChromaDex issued a news release announcing the company's financial results for the first quarter 2018.
CDXC

7
ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018

2018-05-03 globenewswire
IRVINE, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, will report financial results for the first quarter of 2018 on Thurs., May 10, 2018.
CDXC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

26m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CDXC / ChromaDex Corporation on message board site Silicon Investor.

ChromaDex�� Corporation
CUSIP: 171077407